Ammu V. V. V. Ravi Kiran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ammu V. V. V. Ravi Kiran has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Afrasim Moin
Department of Pharmaceutics, College of Pharmacy, University of Hail
1 shared publication - Amr Selim Abu Lila
Department of Pharmaceutics, College of Pharmacy, University of Ha'il, Ha'il 81442, Saudi Arabia
1 shared publication - Asha P. Johnson
Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru 570015, Karnataka, India
1 shared publication - G. Kusuma Kumari
Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Rocklands, Ooty 643001, The Nilgiris, Tamil Nadu, India
1 shared publication - Hosahalli Veerabhadrappa Gangadharappa
Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru 570015, India
1 shared publication - Madhuchandra Kenchegowda
Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research (JSS AHER), Mysuru, India
1 shared publication
Latest Publications
- Open Access
- 18 February 2024
- Published by MDPI AG in Brain Sciences
- Vol. 14 (2) , 185
An Update on Emergent Nano-Therapeutic Strategies against Pediatric Brain Tumors
Pediatric brain tumors are the major cause of pediatric cancer mortality. They comprise a diverse group of tumors with different developmental origins, genetic profiles, therapeutic options, and outcomes. Despite many technological advancements, the treatment of pediatric brain cancers has remained a challenge. Treatment options for pediatric brain cancers have been ineffective due to non-specificity, inability to cross the blood–brain barrier, and causing off-target side effects. In recent years, nanotechnological advancements in the medical field have proven to be effective in curing challenging cancers like brain tumors. Moreover, nanoparticles have emerged successfully, particularly in carrying larger payloads, as well as their stability, safety, and efficacy monitoring. In the present review, we will emphasize pediatric brain cancers, barriers to treating these cancers, and novel treatment options.
- 18 February 2024
- Published by MDPI AG in Brain Sciences
- Vol. 14 (2) , 185
Open AccessAn Update on Emergent Nano-Therapeutic Strategies against Pediatric Brain Tumors
Pediatric brain tumors are the major cause of pediatric cancer mortality. They comprise a diverse group of tumors with different developmental origins, genetic profiles, therapeutic options, and outcomes. Despite many technological advancements, the treatment of pediatric brain cancers has remained a challenge. Treatment options for pediatric brain cancers have been ineffective due to non-specificity, inability to cross the blood–brain barrier, and causing off-target side effects. In recent years, nanotechnological advancements in the medical field have proven to be effective in curing challenging cancers like brain tumors. Moreover, nanoparticles have emerged successfully, particularly in carrying larger payloads, as well as their stability, safety, and efficacy monitoring. In the present review, we will emphasize pediatric brain cancers, barriers to treating these cancers, and novel treatment options.